Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2014; 20(31): 10953-10959
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.10953
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.10953
Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation
Guang-Qin Xiao, Jiu-Lin Song, Shu Shen, Jia-Yin Yang, Lu-Nan Yan, Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Xiao GQ, Song JL, and Shen S contributed equally to this study; Xiao GQ and Yan LN conceived and designed the study; Xiao GQ, Song JL, Shen S, and Yang JY collected data, performed patient follow-up, analyzed the data, and drafted the article; Yan LN and Yang JY revised the manuscript and obtained funding; Xiao GQ, Song JL, Shen S, Yang JY, and Yan LN acquired data, provided technical support, and were involved in the editing of the manuscript.
Supported by National Science and Technology Major Project of China, No. 2012ZX10002-016 and No. 2012ZX10002017-017
Correspondence to: Lu-Nan Yan, MD, PhD, Liver Transplantation Center, West China Hospital of Sichuan University, Nanguoxue, Xiang No. 37, Wuhou District, Chengdu 610041, Sichuan Province, China. yanlunan1268@163.com
Telephone: +86-28-85422867 Fax: +86-28-85422867
Received: November 9, 2013
Revised: March 15, 2014
Accepted: May 23, 2014
Published online: August 21, 2014
Revised: March 15, 2014
Accepted: May 23, 2014
Published online: August 21, 2014
Core Tip
Core tip: Whether there is a higher tumor recurrence for living donor liver transplantation (LDLT) than for deceased donor liver transplantation (DDLT) for hepatocellular carcinoma (HCC) has recently become a subject of debate. Our results suggest that LDLT does not increase the tumor recurrence of HCC compared to DDLT. The recurrence-free survival and long-term survival times of LDLT for HCC are higher than those of DDLT.